Literature DB >> 16425347

Management of functional dyspepsia: Unsolved problems and new perspectives.

Ahmed Madisch1, Stephan Miehlke, Joachim Labenz.   

Abstract

The common characteristic criteria of all functional gastrointestinal (GI) disorders are the persistence and recurrence of variable gastrointestinal symptoms that cannot be explained by any structural or biochemical abnormalities. Functional dyspepsia (FD) represents one of the important GI disorders in Western countries because of its remarkably high prevalence in general population and its impact on quality of life. Due to its dependence on both subjective determinants and diverse country-specific circumstances, the definition and management strategies of FD are still variably stated. Clinical trials with several drug classes (e.g., proton pump inhibitors, H2-blockers, prokinetic drugs) have been performed frequently without validated disease-specific test instruments for the outcome measurements. Therefore, the interpretation of such trials remains difficult and controversial with respect to comparability and evaluation of drug efficacy, and definite conclusions can be drawn neither for diagnostic management nor for efficacious drug therapy so far. In view of these unsolved problems, guidelines both on the clinical management of FD and on the performance of clinical trials are needed. In recent years, increasing research work has been done in this area. Clinical trials conducted in adequately diagnosed patients that provided validated outcome measurements may result in better insights leading to more effective treatment strategies. Encouraging perspectives have been recently performed by methodologically well-designed treatment studies with herbal drug preparations. Herbal drugs, given their proven efficacy in clinical trials, offer a safe therapeutic alternative in the treatment of FD which is often favored by both patients and physicians. A fixed combination of peppermint oil and caraway oil in patients suffering from FD could be proven effective by well-designed clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16425347      PMCID: PMC4355747          DOI: 10.3748/wjg.v11.i42.6577

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  48 in total

1.  Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled double-blind equivalence study.

Authors:  A Madisch; C J Heydenreich; V Wieland; R Hufnagel; J Hotz
Journal:  Arzneimittelforschung       Date:  1999-11

2.  Controlled clinical trial with sucralfate in the treatment of macroscopic gastritis.

Authors:  E Skoubo-Kristensen; P Funch-Jensen; A Kruse; F Hanberg-Sørensen; E Amdrup
Journal:  Scand J Gastroenterol       Date:  1989-08       Impact factor: 2.423

Review 3.  AGA technical review: evaluation of dyspepsia. American Gastroenterological Association.

Authors:  N J Talley; M D Silverstein; L Agréus; O Nyrén; A Sonnenberg; G Holtmann
Journal:  Gastroenterology       Date:  1998-03       Impact factor: 22.682

4.  Clinical trial on the effect of domperidone on non-ulcer dyspepsia.

Authors:  S K Sarin; P Sharma; Y K Chawla; P Gopinath; S Nundy
Journal:  Indian J Med Res       Date:  1986-06       Impact factor: 2.375

5.  Misoprostol treatment exacerbates abdominal discomfort in patients with non-ulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo-controlled, multicentre study.

Authors:  T Hausken; G Stene-Larsen; O Lange; O Aronsen; T Nerdrum; F Hegbom; T Schulz; A Berstad
Journal:  Scand J Gastroenterol       Date:  1990-10       Impact factor: 2.423

6.  Efficacy of a fixed peppermint oil/caraway oil combination in non-ulcer dyspepsia.

Authors:  B May; H D Kuntz; M Kieser; S Köhler
Journal:  Arzneimittelforschung       Date:  1996-12

7.  Ranitidine for non-ulcer dyspepsia. A clinical study of the symptomatic effect of ranitidine and a classification and characterization of the responders to treatment.

Authors:  P G Farup; S Larsen; K Ulshagen; M Osnes
Journal:  Scand J Gastroenterol       Date:  1991-11       Impact factor: 2.423

8.  Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin.

Authors:  R Gotthard; G Bodemar; U Brodin; K A Jönsson
Journal:  Scand J Gastroenterol       Date:  1988-01       Impact factor: 2.423

Review 9.  Geographical differences in the prevalence of dyspepsia.

Authors:  R P Knill-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1991

10.  Cisapride treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo-controlled trial.

Authors:  T Hausken; A Berstad
Journal:  Scand J Gastroenterol       Date:  1992       Impact factor: 2.423

View more
  8 in total

1.  Duodenal intraepithelial T lymphocytes in patients with functional dyspepsia.

Authors:  Gilles Gargala; Stéphane Lecleire; Arnaud François; Serge Jacquot; Pierre Déchelotte; Jean-Jacques Ballet; Loic Favennec; Philippe Ducrotté
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

2.  Quality of life in patients with functional dyspepsia: Short- and long-term effect of Helicobacter pylori eradication with pantoprazole, amoxicillin, and clarithromycin or cisapride therapy: A prospective, parallel-group study.

Authors:  György M Buzás
Journal:  Curr Ther Res Clin Exp       Date:  2006-09

3.  The Diagnosis and Treatment of Functional Dyspepsia.

Authors:  Ahmed Madisch; Viola Andresen; Paul Enck; Joachim Labenz; Thomas Frieling; Michael Schemann
Journal:  Dtsch Arztebl Int       Date:  2018-03-30       Impact factor: 5.594

4.  Translation and validation of the Nepean Dyspepsia Index for functional dyspepsia in China.

Authors:  Xiao-Ping Tian; Ying Li; Fan-Rong Liang; Guo-Jie Sun; Jie Yan; Xiao-Rong Chang; Ting-Ting Ma; Shu-Yuan Yu; Xu-Guang Yang
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

5.  Silicea gastrointestinal gel improves gastrointestinal disorders: a non-controlled, pilot clinical study.

Authors:  B Uehleke; M Ortiz; R Stange
Journal:  Gastroenterol Res Pract       Date:  2012-03-04       Impact factor: 2.260

6.  Sasang constitution affects the prevalence of functional dyspepsia.

Authors:  Yoon Jeong Kim; Yo Chan Ahn; Chang Gue Son
Journal:  BMC Complement Altern Med       Date:  2015-05-20       Impact factor: 3.659

7.  Effect of Apium graveolens and Trachyspermum copticom on clinical symptoms of patients with functional dyspepsia.

Authors:  Maryam Azimi; Mohammad Javad Zahedi; Mitra Mehrabani; Haleh Tajadini; Farzaneh Zolala; Mohammad Reza Baneshi; Rasool Choopani; Fariba Sharififar; Ali Asadipour; Mohammad Mahdi Hayatbakhsh; Bijan Ahmadi
Journal:  Avicenna J Phytomed       Date:  2017 Nov-Dec

8.  Exploratory Study of Tegaserod for Dyspepsia in Women Receiving PPIs for Heartburn.

Authors:  Nimish Vakil; Farid Kianifard; Ivan Bottoli
Journal:  Arch Drug Inf       Date:  2008-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.